ANVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Annovis Bio Inc (ANVS) is not a strong buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, weak financial performance, and lacks significant positive trading signals or catalysts. While the company has promising developments in clinical trials, the financials and technicals do not currently support a strong buy recommendation.
The technical indicators are bearish. The MACD is negative and expanding, RSI is neutral but leaning towards oversold territory, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The price is trading below the key pivot level of 2.549, with support at 2.198 and resistance at 2.9.
The company is conducting a clinical trial for Parkinson's disease using NeuroRPM's FDA-cleared wearable platform, which could provide long-term benefits if successful.
The stock has shown a regular market price decline of -3.15%, and financial performance remains weak with no revenue growth and negative EPS. Additionally, there are no significant trading trends from hedge funds or insiders, and no recent congress trading data.
In Q4 2025, revenue remained at 0 with no YoY growth. Net income improved to -9,834,412 (up 67.69% YoY), but EPS dropped to -0.38 (-5.00% YoY). Gross margin remained at 0.
No recent analyst ratings or price target changes are available for evaluation.
